Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DFAT cell therapy for critical limb ischemia
jRCTb030190212Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous dedifferentiated fat cells in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety of intramuscular injection of DFAT cells. Started Mar 2020; status: completed.
02
Drugs
autologous dedifferentiated fat cells
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCTb030190212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb030190212.